Analyst Ratings For AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO)
Today, HC Wainwright raised its price target on AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) to $9.00 per share.
There are 2 Buy Ratings, no Strong Buy Ratings, no Sell Ratings, no Hold Ratings on the stock.
The current consensus rating on AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) is Buy with a consensus target price of $7.00 per share, a potential 175.59% upside.
Some recent analyst ratings include
- 1/16/2018-AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) had its Buy rating reiterated by B. Riley with a $5.00 price target
- 10/6/2017-AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) had its Buy rating reiterated by Seaport Global Securities
- 7/13/2017-AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) had its Outperform rating reiterated by FBR & Co with a $3.00 price target
- On 8/21/2018 Equity Opportunities Iv Growth, Major Shareholder, bought 663,716 with an average share price of $2.26 per share and the total transaction amounting to $1,499,998.16.
- On 7/19/2018 Equity Opportunities Iv Growth, Major Shareholder, bought 250,600 with an average share price of $1.96 per share and the total transaction amounting to $491,176.00.
- On 6/27/2018 Peter J Barris, Major Shareholder, bought 5,295 with an average share price of $2.15 per share and the total transaction amounting to $11,384.25.
- On 5/30/2018 Equity Opportunities Iv Growth, Major Shareholder, bought 275 with an average share price of $2.15 per share and the total transaction amounting to $591.25.
- On 5/21/2018 Equity Opportunities Iv Growth, Major Shareholder, bought 236,479 with an average share price of $2.13 per share and the total transaction amounting to $503,700.27.
- On 5/17/2018 Ravi Viswanathan, Major Shareholder, bought 184,179 with an average share price of $2.13 per share and the total transaction amounting to $392,301.27.
- On 5/8/2018 Ravi Viswanathan, Major Shareholder, bought 70,873 with an average share price of $2.13 per share and the total transaction amounting to $150,959.49.
About AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO)
AVEO Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes a portfolio of targeted medicines for oncology and other areas of unmet medical need. It markets its lead candidate, tivozanib, an oral, once-daily, vascular endothelial growth factor receptor tyrosine kinase inhibitor, which is used for the treatment of renal cell carcinoma (RCC). The company has also completed a Phase 3 TIVO-3 trial of tivozanib for the treatment of advanced RCC; and initiated enrollment in a phase Ib/II clinical trial of tivozanib in combination with Opdivo (nivolumab), an immune checkpoint (PD-1) inhibitor, for the treatment of advanced RCC. In addition, it is developing Ficlatuzumab, a potent hepatocyte growth factor inhibitory antibody, in Phase I and Phase II clinical trials in squamous cell carcinoma of the head and neck, metastatic pancreatic ductal cancer, and acute myeloid leukemia; and AV-203, a potent anti-ErbB3 specific monoclonal antibody, which has completed Phase I clinical trial for treating esophageal cancer. The company's preclinical stage products include AV-380, a potent humanized IgG1 inhibitory monoclonal antibody for the treatment or prevention of cachexia; and AV-353 for the treatment of pulmonary arterial hypertension. It has strategic partnerships with CANbridge Life Sciences Ltd.; EUSA Pharma (UK) Limited; Novartis International Pharmaceutical Ltd.; Biodesix, Inc.; St. Vincent's Hospital Sydney Limited; Biogen Idec; and Kyowa Hakko Kirin Co., Ltd. The company was formerly known as GenPath Pharmaceuticals, Inc. and changed its name to AVEO Pharmaceuticals, Inc. in March 2005. AVEO Pharmaceuticals, Inc. was incorporated in 2001 and is based in Cambridge, Massachusetts.
Recent Trading Activity for AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO)
Shares of AVEO Pharmaceuticals, Inc. closed the previous trading session at 2,54 −0,25 8,96 % with 6418400 shares trading hands.
